Document Detail


beta-blockers or calcium antagonists in silent ischaemia?
MedLine Citation:
PMID:  7903246     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Unrecognized or silent myocardial ischaemia during daily life has generated considerable recent interest as it occurs in all forms of coronary artery disease, ranging from those who are totally asymptomatic to those who have had a myocardial infarction. A characteristic diurnal cycle of both frequency and duration of these ischaemic episodes occurs and is the same as the diurnal variation observed in frequency of acute myocardial infarction and out-of-hospital sudden death. These findings suggest common underlying triggering mechanisms which may couple transient ischaemia to these morbid events. The presence of daily-life silent ischaemia is associated with a two- to five-fold increase in risk of death and similar increases in risk of non-fatal infarction. Multivariate analysis suggests that silent ischaemia is the best independent predictor of outcome (e.g. death, or myocardial infarction) among a number of factors that include coronary angiography and exercise test results. Anti-anginal agents (e.g. nitrates, beta-blockers, calcium antagonists) also reduce or prevent daily-life silent ischaemia. While anti-anginal treatment can control both symptomatic and silent ischaemic episodes, therapy directed towards symptom control alone may be insufficient to control recurrent silent ischaemia in many individuals. A recent report suggests that suppression of painless ischaemia by anti-ischaemic treatment is associated with a reduced risk of adverse outcome. Additional advances in this area will require the results of large, well-controlled multicentre clinical trials, several of which are currently in progress.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
C J Pepine
Related Documents :
11565616 - The regional changes of the catalytic nos activity in the spinal cord of the rabbit aft...
1736566 - The predictive value of silent ischemia at an exercise test before discharge after an e...
24642696 - Impaired coronary flow reserve is the most important marker of viable myocardium in the...
24562806 - Relationship between st-segment resolution and anterior infarct size after primary perc...
1623736 - Ventricular function in snorers and patients with obstructive sleep apnea.
7215366 - Validity of different gated equilibrium blood pool methods for determination of left ve...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  European heart journal     Volume:  14 Suppl F     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1993 Oct 
Date Detail:
Created Date:  1994-01-21     Completed Date:  1994-01-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  7-14     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Florida College of Medicine, Gainesville.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Calcium Channel Blockers / therapeutic use*
Clinical Trials as Topic
Drug Therapy, Combination
Humans
Myocardial Ischemia / drug therapy*,  mortality,  physiopathology
Risk Factors
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Calcium Channel Blockers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Calcium antagonists or beta-blockers in chronic ischaemic left ventricular dysfunction?
Next Document:  Forskolin blocks the apical expression of dipeptidyl peptidase IV in Caco-2 cells and induces its re...